This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. | As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new U.S. owner in Rigel Pharmaceuticals.
By settling now and agreeing to deferred payments over the next five years, Novavax avoids the risk of being responsible for a much bigger payout all at once. The arbitration hearing over the disputed vaccine purchase agreement with Gavi was scheduled for this summer.
Regeneron and Sanofi have reached another milestone as they look to add to their megablockbuster immunology drug Dupixent a new U.S. | Regeneron and Sanofi have reached another milestone is their advancement of Dupixent (dupilumab) as a potential treatment for uncontrolled chronic obstructive pulmonary disease (COPD) with type 2 inflammation as the FDA has accepted the companies’ application and designated it for priority review with a target action date of June 27.
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
To get a pulse on Moderna following its “year of transition” in 2023, look no further than the company’s manufacturing operations. | To get a pulse on Moderna following its “year of transition” in 2023, look no further than the company’s manufacturing operations. The Cambridge, Massachusetts-based biotech has incurred a COVID-related wind-down charge on one hand, while it spends millions of dollars to bolster cancer vaccines at the same time.
About 80% of all FDA-approved healthcare AI applications are related to radiology — but due to a massive workforce shortage, radiologists don’t have the time to explore, choose, validate and implement the tools available to them. Some providers are using a radiology AI marketplace called CARPL to address this problem, including Massachusetts General Hospital and University Hospitals.
While the overall theme of Moderna’s quarterly earnings presentation on Thursday was that the company is moving away from its coronavirus vaccine and onto a host of other mRNA products in developme | In the fall vaccination season, Moderna captured 48% of the COVID-19 retail market in the United States versus a 37% showing in 2022, closing the gap on Pfizer’s Comirnaty.
While the overall theme of Moderna’s quarterly earnings presentation on Thursday was that the company is moving away from its coronavirus vaccine and onto a host of other mRNA products in developme | In the fall vaccination season, Moderna captured 48% of the COVID-19 retail market in the United States versus a 37% showing in 2022, closing the gap on Pfizer’s Comirnaty.
Daiichi Sankyo is building additional antibody-drug conjugate capacity at its German site. Astellas partnered with Kelonia on cell therapy tech. | Daiichi Sankyo is investing 1 billion euros to expand its German site. Astellas partnered with Kelonia on cell therapy tech. Novartis launched a strategic review of a subsidiary in India that's focused on older meds.
More digital health consolidation as Aptar buys Healint, a specialist in patient support apps and software to run virtual clinical trials and patient registries
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
February 22, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host the Town Hall event “The Heart of the Matter: Copyright, AI Training and LLMs” via LinkedIn Live on Thursday, 29 February, 11:00 EST/16:00 GMT. A panel of legal experts including Prof. Daniel Gervais , Vanderbilt University Law School, and Prof.
Now more than ever, enhancing primary care practices to include CGM capabilities is a crucial goal requiring the support and involvement of the broader healthcare community.
NICE has backed NHS use of Pfizer’s Litfulo for patients with alopecia areata, the first drug therapy for a condition that affects around 14,000 people
Are you a biopharma startup focused on oncology? A devices /diagnostics startup focused on cardiology? Or a health tech startup focused on how consumers/employers are addressing women’s health? If so, submit an application for MedCity INVEST Pitch Perfect by February 29!
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Perelel’s $10 million pledge comes in the form of product donations and funding grants and will go to the Magee-Womens Research Institute and the Good+Foundation through 2027.
A cohort study investigates how a change in clinical guidelines, an expanded label, and reduction in drug prices can impact the use of PCSK9 inhibitors as a treatment for atherosclerotic cardiovascular disease.
In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.
A report by Towards Healthcare has forecasted that the advanced drug delivery market will value $375.86 billion by 2033. The year 2023 was “significant” for the progress of advanced drug delivery systems, the author reflected. Last year, with a size of $234.84 billion, the market witnessed “remarkable advancements that promise to reshape healthcare landscapes across the globe”.
The National Institute for Health and Care Excellence (NICE) has recommended LITFULO ® (ritlecitinib) for treating certain patients with severe alopecia areata. This is “an important milestone” according to Lynn Clay, Specialty Care Lead at Pfizer UK. The once daily oral capsule is indicated as a treatment option in individuals who are 12 years and older.
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Clients partner with Clarivate consultants for many reasons, including strategic perspective, additional skills, complementary data sets and therapy expertise. In the research and development space, we help companies advance their drug discovery, preclinical proof-of-concept, and regulatory activities. Clarivate’s translational science expertise, regulatory and commercial experts and assets combine to complement client teams in generating long term value.
Patients and other stakeholders need to be able to compare pharmacies based on standardized, transparent metrics with a measurement system to make informed decisions.
As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.
Small medical device companies often face unique challenges such as limited resources, intense competition, and a need for precise and compliant communication. Navigating through these challenges can be daunting, but knowing how to build a sales team can be the key to success. But building a high-performing sales team will need a ton of strategy, hard work, and persistence.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content